Syngene
Syngene International Limited, commonly referred to as Syngene, is a leading global contract research and manufacturing organisation headquartered in Bengaluru, India. Founded in 1993, Syngene has established itself as a key player in the biopharmaceutical industry, providing integrated research and development services to clients across the globe. With a strong presence in North America, Europe, and Asia, Syngene offers a diverse range of services, including drug discovery, development, and manufacturing. The company is renowned for its innovative approach, leveraging cutting-edge technologies to deliver high-quality solutions tailored to client needs. Syngene's commitment to excellence has earned it a prominent market position, with notable achievements in collaborations with major pharmaceutical companies. Its unique blend of scientific expertise and operational efficiency sets Syngene apart in the competitive landscape of life sciences.
DitchCarbon Score
How does Syngene's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syngene's score of 67 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syngene's reported carbon emissions
In 2024, Syngene International Limited reported total greenhouse gas emissions of approximately 61,010,000 kg CO2e for Scope 1, 13,012,000 kg CO2e for Scope 2, and 48,780,000 kg CO2e for Scope 3. This reflects a slight increase in Scope 1 emissions from 60,030,000 kg CO2e in 2023, while Scope 2 emissions decreased from 18,765,000 kg CO2e. Scope 3 emissions also saw a reduction from 89,418,000 kg CO2e in 2023. Syngene has set ambitious climate commitments, aiming to reduce its absolute Scope 1 emissions by 30% and Scope 2 emissions by 25% from a 2021 baseline by 2030. Additionally, the company has committed to a significant long-term target of reducing absolute Scope 1 and 2 GHG emissions by 54.6% by FY2033, using FY2023 as the base year. Furthermore, Syngene aims for 81.6% of its suppliers to have science-based targets by FY2028, covering emissions from purchased goods and services, capital goods, and upstream transportation and distribution. These targets align with industry standards and demonstrate Syngene's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. The company has not yet committed to a net-zero target but continues to work towards substantial emissions reductions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 3,440,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,263,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 62,847,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syngene is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
